Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-17T18:01:35.120Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment in obsessive – compulsive disorder with high dosage of sertraline (asentra) and low dosage of olanzepine(zalasta)

Published online by Cambridge University Press:  16 April 2020

S. Arsova ,
V. Vujovic ,
G. Hadzi-Angelkovski ,
V. Gerazova ,
A. Novotni ,
M. Stanoevska ,
L. Aleksovska ,
N. Simonovski  and
Z. Babinkostova
S. Arsova
Affiliation:
Psychiatric Clinic, Skopje, Macedonia
V. Vujovic
Affiliation:
Psychiatric Clinic, Skopje, Macedonia
G. Hadzi-Angelkovski
Affiliation:
Psychiatric Hospital, Skopje, Macedonia
V. Gerazova
Affiliation:
Psychiatric Clinic, Skopje, Macedonia
A. Novotni
Affiliation:
Psychiatric Clinic, Skopje, Macedonia
M. Stanoevska
Affiliation:
KRKA, Skopje, Macedonia, Skopje, Macedonia
L. Aleksovska
Affiliation:
Medical Ambulance, JPAU, Skopje, Macedonia
N. Simonovski
Affiliation:
Psychiatric Hospital, Skopje, Macedonia
Z. Babinkostova
Affiliation:
Psychiatric Clinic, Skopje, Macedonia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aim of the work

To follow the efficiency in treating the obsessive-compulsive disorders in higher dosages of Asentra and low dosages of Olanzepine as an augment of the pharmacological treatment in the obsessive-compulsive symptoms in these patients.

Materials and methods

During the research we included 30 patients with long-term obsessive-compulsive symptoms. They were chosen randomly, treated in an out-patient clinic as well as in the Psychiatric clinic. The patients were of both sexes, aged 25-45. In all patients serious somatic diseases were excluded. They were observed by HAMD, HAS, 18 PF(18 Personality Factor-Katel), Scale for measuring the obsession, compulsion and schizophrenia and it was done twice: in the beginning and after three months constant treatment with Asentra tablets in dosages of 100-300mg and Zalasta tablets in dosages of 2,5-5mg per day.

Results:

In 12 patients there was an improvement which resulted in score decline of the HAS, HAMD, and 18 PF (18 Personality Factor-Katel). In 8 patients there was a slight improvement. And in 10 patients there was no significant improvement.

Conclusion:

High dosages of Asentra given in combination with Olazepine for anxiety treatment and as an augment of the anti-depressive are efficient and safe in treating patients with obsessive-compulsive disorders.

Type
Poster Session 1: Mental Health, Caregivers Issues and Social Psychiatry
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S215
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.